Pharmacological basis of allotransplantation
Specific cyclic antibiotics form the basis of modern immunosuppressive therapy in organ transplantation. A historical breakthrough in this field occurred in the 1980s due to the widespread clinical introduction of a drug called cyclosporine. It was this crucial step that allowed medicine to achieve today's high graft survival rates. Today, this same group of drugs also includes tacrolimus (known as FK506) and rapamycin.
Despite sharing a common ultimate goal, the molecular mechanisms of action of these drugs differ:
- Cyclosporine and tacrolimus intervene in cell function at early stages. They interrupt intracellular calcium-dependent (Ca2+) signaling. As a result, the translocation (movement into the cell nucleus) of the NF-AT transcription factor is reliably blocked. The outcome of this action is the inability to activate lymphocytes, a complete halt in interleukin-2 (IL-2) synthesis, and suppression of T-lymphocyte clonal expansion.
- Rapamycin acts at a different biochemical stage. This drug strictly blocks signal transduction directly from the interleukin-2 (IL-2) receptor, rendering the cell unresponsive to external stimulating factors.
Use of antibodies to prevent rejection
The evolution of antibody-based immunosuppressive therapy has journeyed from crude methods to high-precision biotechnology. Initially, physicians used antilymphocyte sera and antilymphocyte globulin. These were polyclonal antibodies against various lymphocyte membrane molecules. This initial approach had numerous critical flaws: the composition of the drugs was extremely heterogeneous, their specificity remained low, and the solutions contained many ballast impurities.
The modern clinical standard is the use of monoclonal antibodies that bind strictly to specific T-lymphocyte membrane antigens. Antibodies against the CD3 molecule demonstrate high efficacy. However, a crucial safety rule lies here: only blocking antibodies are permitted for use in therapy. If activating molecules are mistakenly used, a catastrophic polyclonal activation of T cells will occur, accompanied by a massive and life-threatening cytokine release.
For a long time, the antigenicity of drugs remained a serious problem. The first generations of monoclonal antibodies were derived from murine cells, so the human immune system naturally recognized them as foreign proteins. To circumvent this problem, researchers developed a complex procedure for "humanization" of antibody molecules. Currently, one of the most promising areas is the development of rejection-suppression methods using antibodies directed against costimulatory receptors (for example, the CD80 molecule).
Blood transfusion as a variant of allotransplantation
From an immunological perspective, blood transfusion is a specific variant of allogeneic tissue transplantation. This method began to be implemented in medical practice after K. Landsteiner (K. Landsteiner) discovered blood groups in 1900. This historical event is significant because the first system of antigenic polymorphism in humans was established.
The features of tissue incompatibility in blood transfusion differ significantly from solid organ transplantation:
- Temporary effect. The procedure is designed solely for the transfer of erythrocytes to urgently restore gas exchange. Long-term engraftment of donor cells in the recipient's body is not required.
- Nature of antigens. Incompatibility is caused exclusively by erythrocyte alloantigens. Leukocytes do not play a leading role in this process, which completely eliminates the problem of incompatibility via the major histocompatibility complex (MHC).
The mechanism of incompatibility development is triggered if the recipient already has antibodies specific to the donor erythrocyte alloantigens prior to the transfusion. Such prior immunization occurs for several reasons. First, due to repeated blood transfusions from the same donor (strictly not practiced in modern medicine to avoid complications). Second, due to repeated pregnancies from the same partner, which is of paramount importance for fetal preservation in Rh (rhesus factor) incompatibility.
Briefly: answers to topical questions
What is the role of the CD80 molecule in modern immunosuppressive therapy?
In modern immunosuppressive therapy, the CD80 molecule is considered a promising target for developing methods to suppress transplant rejection using antibodies.
The CD80 molecule (B7-1) participates in two pathways of immune response regulation:
- upon binding to the CD28 receptor, it promotes the activation of the immune response;
- upon binding to the CTLA-4 receptor, it transmits a suppressive signal.
The development of antibodies against costimulatory molecules, such as CD80, is viewed as a promising direction for suppressing transplant rejection.
What clinical indications exist for the use of immunosuppressive therapy?
The main clinical indication for the use of immunosuppressive therapy is allotransplantation.
The therapy is used to prevent transplant rejection. The main agents used are:
- Tacrolimus (FK506) is a cyclic antibiotic that interrupts Ca2+-dependent signaling and blocks the translocation of the NF-AT factor into the nucleus, which prevents cell activation, IL-2 synthesis, and T-lymphocyte clonal expansion.
- Monoclonal blocking antibodies against CD3 are used to prevent transplant rejection.
The use of cyclosporine since the 1980s has made it possible to achieve the modern level of allotransplantation efficacy.
For quick memorization of cyclic antibiotic sites of action: cyclosporine and tacrolimus work "at the start" (depriving the cell of the ability to produce IL-2 by blocking the NF-AT factor), while rapamycin works "at the finish" (muffling the signal from the receptor to the already formed IL-2).
Class and exam questions
Why doesn't a major histocompatibility complex (MHC) mismatch occur during blood transfusion?
Transfusion mismatch is caused by erythrocyte alloantigens. Leukocytes, which carry MHC molecules, do not cause clinically significant incompatibility in this case.
What is the danger of using murine monoclonal antibodies?
The human body recognizes murine antibodies as foreign agents (exhibiting their antigenicity) and destroys them. To solve this problem, pharmacology applies the mandatory procedure of "humanization".
What happens if activating antibodies against CD3 are administered to a patient?
The use of activating antibodies will cause generalized polyclonal activation of T lymphocytes. This will lead to a massive release of cytokines, which is extremely dangerous for the patient.
What else to study on this topic
- Mechanism of Ca2+-dependent signaling in T lymphocytes
- The role of the NF-AT transcription factor in the immune response
- "Humanization" technology for monoclonal antibodies
- Immunological conflict via the Rh system (rhesus factor) during pregnancy
- The significance of the CD80 molecule and other costimulatory receptors
Master the entire topic in the "Immunology" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Immunosuppressive therapy" and 723 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 23 video lessons on the subject
Other topics in the section "Immunity in defense and damage of the organism. Pathology of immunity"
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.